Prognosis analysis of 216 cases of gastrointestinal stromal tumor.
- Author:
Li-cheng LIU
1
;
Wen-tong XU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; therapeutic use; Benzamides; therapeutic use; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; drug therapy; surgery; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; therapeutic use; Prognosis; Pyrimidines; therapeutic use; Retrospective Studies; Survival Rate; Young Adult
- From: Chinese Journal of Gastrointestinal Surgery 2012;15(3):255-258
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the impact of location of gastrointestinal stromal tumor(GIST) on the survival, and the influence of surgical treatment and imatinib therapy on survival.
METHODSThe clinical data of 216 patients with GIST who were admitted to the People's Liberation Army Hospital from January 2004 to December 2010 were analyzed retrospectively.
RESULTSAll the patients were followed up with a median time of 22 months(1 to 83 months). The 1-, 3-, and 5-year survival rates were 93%, 75% and 30%. The survival rates of 5-year with GIST located in the stomach (103 cases), the small intestine (45 cases) and gastrointestinal outside(41 cases) were 93%, 75%, and 30%, respectively, and the differences were statistically significant(P<0.05). There were no deaths in patients with GIST located in duodenum(18 cases) and rectum(9 cases). The 5-years survival rates of GIST in the groups of complete excision combined with imatinib, complete resection without imatinib, incomplete resection combined with imatinib, incomplete resection without imatinib were 100%, 98%, 49% and 14%, respectively, and the differences were statistically significant(P<0.05).
CONCLUSIONSGISTs in different parts of gastrointestinal tract have different survival rates. Radical resection and imatinib can improve the survival rates of patients with GIST.
